Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gentulizumab Phase Ia in Advanced Solid Tumors and NHL
NCT05221385Phase 1Terminated
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2021
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gentulizumab in solid tumor and non-Hodgkin lymphoma (NHL), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Safety and Tolerability of Gentulizumab (DLTs, AEs, SAEs) at 28 days, Area under the plasma concentration versus time curve at 90 days and 2 more. Started Apr 2021; status: terminated.
02
Drugs
gentulizumab
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05221385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05221385.